Our Pricing

Wegovy vs Mounjaro UK: Complete Price and Efficacy Comparison

When comparing Wegovy vs Mounjaro UK options, patients consistently ask which weight loss injection offers better value and clinical outcomes. Both semaglutide (Wegovy) and tirzepatide (Mounjaro) are MHRA-licensed prescription treatments that have demonstrated significant weight reduction in clinical trials, yet they differ substantially in mechanism, dosing frequency, and cost. At Cured Pharmacy, our UK-registered clinical team has guided thousands of patients through this decision, providing transparent pricing and evidence-based recommendations tailored to individual health profiles.

How Wegovy vs Mounjaro UK Mechanisms Differ

Understanding the pharmacological difference between Wegovy vs Mounjaro UK treatments is essential for informed decision-making. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the glucagon-like peptide-1 hormone to reduce appetite and slow gastric emptying [1]. Mounjaro utilises tirzepatide, a dual GIP/GLP-1 receptor agonist that activates both glucose-dependent insulinotropic polypeptide and GLP-1 pathways, potentially offering enhanced metabolic benefits [2].

The dual-agonist mechanism in Mounjaro may explain why clinical trials have shown marginally higher average weight loss compared to single-agonist therapies. However, both medications require subcutaneous injection once weekly and are prescribed only after comprehensive clinical assessment by a UK-registered prescriber. Patients with type 2 diabetes history may find Mounjaro's glucose-regulating properties particularly beneficial, though Wegovy remains highly effective for weight management in non-diabetic populations [3].

Active Ingredient Comparison

Semaglutide in Wegovy has been extensively studied since its approval for weight management, with the STEP trial programme demonstrating average weight loss of 15-17% over 68 weeks in participants without diabetes [1]. Tirzepatide in Mounjaro showed average reductions of 15-22% in the SURMOUNT-1 trial, with higher doses achieving greater outcomes [2]. Both medications are supplied as pre-filled injection pens and require refrigeration before first use, though Mounjaro's dosing escalation schedule differs slightly from Wegovy's structured titration protocol.

Wegovy vs Mounjaro UK Price Breakdown at Cured Pharmacy

Transparent pricing is fundamental when evaluating Wegovy vs Mounjaro UK options, as cost often influences long-term treatment adherence. At Cured Pharmacy, Wegovy starts from £124.99 per month, whilst Mounjaro is priced from £124.99 monthly, both representing competitive UK pricing with no hidden consultation fees. New patients receive £20 off their first order using code Weightlossnew, and our superintendent pharmacist Tarun Kumar ensures every prescription meets MHRA standards before dispensing.

The price difference reflects manufacturing costs, market positioning, and dose availability rather than clinical superiority. Both treatments require ongoing monthly prescriptions subject to prescriber approval, and our UK-registered clinical team provides free consultations under three minutes to assess suitability. Patients should budget for at least 6-12 months of treatment to achieve clinically meaningful weight loss, as both medications demonstrate optimal results with sustained use [3].

Clinical Efficacy: Wegovy vs Mounjaro UK Trial Data

When assessing Wegovy vs Mounjaro UK efficacy, direct comparison trials remain limited, but individual study data provides valuable insight. The STEP 1 trial showed participants on semaglutide 2.4mg lost an average of 14.9% body weight compared to 2.4% with placebo over 68 weeks [1]. The SURMOUNT-1 trial reported tirzepatide 15mg users achieved average weight reduction of 22.5% versus 2.4% placebo at 72 weeks [2].

These results suggest Mounjaro may offer slightly higher average weight loss at maximum doses, though individual response varies considerably based on adherence, lifestyle modifications, and metabolic factors. Both medications demonstrated cardiovascular benefits and improvements in obesity-related comorbidities including hypertension and dyslipidaemia [4]. UK prescribers typically select treatment based on patient history, tolerance to GLP-1 therapies, and cost considerations rather than efficacy alone.

Weight Loss Timeframes

Patients commonly observe initial weight reduction within 4-8 weeks of starting either Wegovy or Mounjaro, with progressive loss continuing throughout the titration phase. Maximum therapeutic effect typically occurs between months 6-12, provided patients maintain caloric restriction and regular physical activity. Clinical trials required participants to follow reduced-calorie diets and exercise programmes, emphasising that medication alone cannot replace comprehensive lifestyle intervention [1][2].

Side Effect Profile: Wegovy vs Mounjaro UK Comparison

Tolerability is a critical consideration when choosing between Wegovy vs Mounjaro UK treatments, as gastrointestinal side effects represent the most common reason for discontinuation. Both medications frequently cause nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation phases [1][2]. Clinical trial data indicates approximately 44% of Wegovy users and 47% of Mounjaro users experienced nausea, though symptoms typically diminish after several weeks as the body adapts.

Serious adverse events remain rare but include pancreatitis risk (estimated at 0.2-0.3% across GLP-1 therapies), gallbladder disorders, and potential thyroid C-cell tumours observed in rodent studies [4]. Both medications carry black box warnings regarding medullary thyroid carcinoma risk and are contraindicated in patients with personal or family history of MEN 2 syndrome. Our clinical team conducts thorough medical history reviews during online consultations to identify contraindications before prescribing either treatment.

Dosing Schedules: Wegovy vs Mounjaro UK Titration

The titration protocols for Wegovy vs Mounjaro UK injections differ in escalation speed and maximum doses. Wegovy follows a five-month titration starting at 0.25mg weekly, increasing monthly through 0.5mg, 1mg, 1.7mg, to the maintenance dose of 2.4mg [1]. Mounjaro begins at 2.5mg weekly, escalating every four weeks through 5mg, 7.5mg, 10mg, 12.5mg, to a maximum of 15mg depending on tolerance and efficacy [2].

Both regimens aim to minimise gastrointestinal side effects whilst achieving therapeutic weight loss. Patients who experience persistent nausea may remain at lower doses longer under prescriber guidance, though this may reduce overall efficacy. The once-weekly injection schedule for both medications offers convenience compared to daily treatments like Saxenda, improving long-term adherence rates observed in real-world UK pharmacy settings.

Injection Technique and Storage

Both Wegovy and Mounjaro are supplied as pre-filled single-use pens for subcutaneous injection into the abdomen, thigh, or upper arm. Unused pens must be refrigerated at 2-8°C, whilst in-use pens can be stored at room temperature up to 30°C for 28 days (Wegovy) or 21 days (Mounjaro). Proper injection technique training is provided through patient information leaflets, and our pharmacy team offers telephone support for patients requiring additional guidance on administration or storage requirements.

Which Treatment Offers Better Value: Wegovy vs Mounjaro UK

Determining value in the Wegovy vs Mounjaro UK comparison requires balancing cost, efficacy, and individual tolerance. Wegovy's lower monthly price point (from £124.99 at Cured Pharmacy) makes it more accessible for long-term use, particularly for patients funding treatment privately without insurance coverage. The established evidence base and longer UK market presence provide additional confidence for prescribers and patients alike [1].

Mounjaro may justify its higher cost (from £124.99) for patients seeking maximum weight loss outcomes or those with concurrent type 2 diabetes requiring enhanced glycaemic control [2]. However, the 6-8% price difference should be weighed against individual response, as some patients achieve excellent results with Wegovy at lower cost. Our UK-registered clinical team evaluates medical history, weight loss goals, budget constraints, and previous GLP-1 therapy experience to recommend the most appropriate option during the free online consultation.

Both treatments represent significant investment compared to traditional weight management approaches, yet clinical trial data demonstrates superior efficacy versus lifestyle intervention alone [3][4]. Patients should commit to minimum 6-month treatment courses to assess true effectiveness, as premature discontinuation often results in weight regain. Cured Pharmacy's transparent upfront pricing and £124.99 new patient discount (code Weightlossnew) help reduce initial financial barriers whilst maintaining the highest UK pharmacy standards under GPhC registration 9012511.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Wadden, T. A. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Tirzepatide (Mounjaro) for weight management. MHRA UK. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.